Eloxx Pharmaceuticals, Inc.
ELOXNasdaq
$12.00
↓ -0.2%Jul 17 close · end-of-day
Price
1Y↑ +1090809.1%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$148.2M
Enterprise Value
$141.8M
P/E
—
P/S
—
P/B
—
EV/EBITDA
—
PEG
—
FCF Yield
—
Dividend Yield
—
Revenue (TTM)
$0.00
Net Income (TTM)
-$6.0M
Free Cash Flow (TTM)
—
Gross Margin
—
Operating Margin
—
Net Margin
—
ROE
79.0%
ROIC
—
Debt / Equity
0.0
Net Cash
$6.4M
Return 1Y
+1090809.1%
Company profile
We are a clinical-stage biopharmaceutical company developing novel, small molecule product candidates designed to modulate the ribosome and promote readthrough of premature stop codons induced by nonsense mutations (“NMs”) to enable the production of full-length proteins. The address of our principal executive offices is in Arlington, MA.
- CEO
- Sumit Aggarwal
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 10
- Headquarters
- Massachusetts
- Website
- eloxxpharma.com
Earnings
ELOX Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue——
Diluted EPS-$0.08↓ -82.2%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | — | — | — | $0.00 | $6.4M | $0.00 |
| Gross profit | — | — | — | — | — | — |
| Operating income | -$33.5M | -$66.0M | -$34.4M | -$17.3M | -$2.5M | -$6.4M |
| Net income | -$34.6M | -$66.7M | -$36.1M | -$17.1M | -$3.1M | -$6.0M |
| Diluted EPS | — | -$38.15 | -$16.65 | -$6.63 | -$0.84 | -$0.49 |
| Operating cash flow | -$28.2M | -$35.0M | -$31.8M | -$14.3M | -$4.7M | -$6.3M |
| Free cash flow | — | -$35.1M | -$31.9M | — | — | — |
| Gross margin | — | — | — | — | — | — |
| Operating margin | — | — | — | — | -38.8% | — |
| Net margin | — | — | — | — | -49.4% | — |
| Line item | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | -$7.1M | -$6.0M | -$5.5M | -$4.1M | -$3.6M | -$4.0M | -$1.2M | -$3.8M |
| Net income | -$7.5M | -$6.3M | -$6.2M | -$4.3M | -$3.6M | -$2.9M | -$1.7M | -$3.8M |
| Diluted EPS | -$3.47 | -$2.92 | -$2.88 | -$1.96 | -$1.31 | -$0.48 | -$0.45 | -$0.08 |
| Operating cash flow | -$6.9M | -$5.7M | -$6.8M | -$2.1M | -$3.5M | -$2.0M | $1.2M | -$5.5M |
| Free cash flow | -$7.0M | -$5.7M | -$6.8M | -$2.1M | -$3.5M | — | — | — |
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | — | — | — | — | — | — | — | — |
| Net margin | — | — | — | — | — | — | — | — |
Company news
Apr 16, 2024
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
No insider transactions in the last 12 months.
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-06-10 | Domicilium Real Estate Fund III LP | J | 238,422 | — | — | filing |
| 2026-06-10 | Domicilium Real Estate Fund III LP | J | 361,578 | — | — | filing |
| 2026-05-27 | Domicilium Real Estate Fund III LP | J | 113,636 | $0.00 | $0.00 | filing |
| 2026-05-27 | Coastlands Capital LP | J | 1,250,000 | $0.00 | $0.00 | filing |
| 2026-01-24 | Rubin Steven D | Option exercise | 1,875 | — | — | filing |
| 2026-01-24 | Walts Alan Edmund | Option exercise | 1,875 | — | — | filing |
Latest 6 transactions.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.